DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)

South Korea · Delayed Price · Currency is KRW

3,385.00

-15.00 (-0.44%)

At close: Nov 13, 2026

Market Cap	91.54B -37.3%
Revenue (ttm)	241.43B -0.5%
Net Income	33.01B +453.6%
EPS	1,190.89 +445.6%
Shares Out	27.04M
PE Ratio	2.84
Forward PE	n/a
Dividend	120.00 (3.55%)
Ex-Dividend Date	Dec 29, 2026

Volume	90,999
Open	3,430.00
Previous Close	3,400.00
Day's Range	3,210.00 - 3,430.00
52-Week Range	3,055.00 - 6,300.00
Beta	0.35
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About DongKoo Bio & Pharma

DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antip... [Read more]

Industry Pharmaceutical Preparations

Founded 1970

Employees 383

Stock Exchange KOSDAQ

Ticker Symbol 006620

Full Company Profile

Financial Performance

In 2025, DongKoo Bio & Pharma's revenue was 242.69 billion, a decrease of -2.64% compared to the previous year's 249.27 billion. Earnings were 50.27 billion, an increase of 2369.74%.

Financial Statements